sales till june 2008, page-2

Don't think so mal you must be new. The demand for this is huge, $70million a year in Russia alone in 2yrs for Ropren. Then take into account all other products all other countries and multi uses for Ropren, won't just be for 1 application. If you think $1.25 is too high to pay move onto something else then and leave us to get more on dips.

Don't worry about options being cashed no one is selling their shares just directors and others buying more. You are entitled to your opinion however. You can't PE THIS and PE that when you have a wonderdrug blockbuster company about to hit the world and media trail.

Good luck with your Bluechips however.